


Supplementary Materials

# Use of Cardiac Biomarkers for Monitoring Improvement of Left Ventricular Function by Immunoabsorption Treatment in Dilated Cardiomyopathy

Karolina Weinmann, Jakob Werner, Wolfgang Koenig, Wolfgang Rottbauer, Daniel Walcher and Mirjam Kessler \*


Department of Internal Medicine II, University Ulm Medical Center, Ulm, Germany

\* Correspondence: mirjam.kessler@uniklinik-ulm.de; Tel.: +49 731 500 45064; Fax: +49 731 500 45005



**Figure S1.** Drop of circulating IgG levels during immunoabsorption treatment.

Table S1. Heart failure medication.



Graphs display the mean percentage of patients that received the respective medication, AT1/ACE = AT1/ACE-blocker, BB = Beta-blocker MRA = mineralocorticoid receptor antagonist, ID = initial diagnosis, IA = before immunoadsorption treatment, FU = long-term follow-up, % max. = mean % of maximum equivalent dosage.

Table S2. Correlation of  $\Delta$  HF biomarker with comorbidities.

	$\Delta$ sST2	$\Delta$ NT-proBNP	$\Delta$ hs troponin T	$\Delta$ hs troponin I
<b>Creatinine before IA</b>	$r = -0.01$ $p = 0.98$	$r = -0.04$ $p = 0.8$	$r = 0.04$ $p = 0.8$	$r = -0.1$ $p = 0.6$
<b>Creatinine at FU</b>	$r = -0.1$ $p = 0.6$	$r = -0.1$ $p = 0.6$	$r = 0.1$ $p = 0.7$	$r = -0.05$ $p = 0.8$
<b>Hb before IA</b>	$r = 0.02$ $p = 0.92$	$r = 0.3$ $p = 0.08$	$r = -0.02$ $p = 0.9$	$r = -0.05$ $p = 0.8$
<b>Hb at FU</b>	$r = 0.02$ $p = 0.9$	$r = -0.1$ $p = 0.6$	$r = -0.1$ $p = 0.5$	$r = -0.04$ $p = 0.8$
<b>BMI before IA</b>	$r = -0.09$ $p = 0.6$	$r = 0.1$ $p = 0.6$	$r = -0.04$ $p = 0.8$	$r = -0.2$ $p = 0.4$
<b>BMI at FU</b>	$r = -0.07$ $p = 0.7$	$r = 0.3$ $p = 0.2$	$r = -0.2$ $p = 0.4$	$r = -0.2$ $p = 0.4$
<b>Age before IA</b>	$r = -0.18$ $p = 0.3$	$r = -0.01$ $p = 0.96$	$r = 0.1$ $p = 0.6$	$r = -0.1$ $p = 0.6$

